展覽5.1
客戶：23553-00003
2024年10月1日
Dianthus Therapeutics, Inc.
7 帝國廣場，43號rd
紐約市，紐約州10036 電話：+1 646 397 3970
| 關於： | Dianthus Therapeutics, Inc. |
號碼：333-280982 S-3
女士們先生們：
我們已成爲Dianthus Therapeutics, Inc.的律師，一家特拉華州的公司（“公司），現專門與證券交易委員會（以下簡稱「交易委員會」）準備和提交一份S-3表格的註冊聲明（以下簡稱「註冊聲明」）。委員會:表格號：333-280982 S-3 (「本登記聲明」) 由特立軟件股份有限公司，一家德拉華州股份公司 (以下簡稱爲「本公司」) 提交，目的是爲了註冊其額外的7,184,563股A類普通股，每股面值$0.0001 (以下簡稱爲「A類普通股」), 以及在特立軟件股份有限公司 2022年股權激勵計劃下可發行股份的1,436,911股A類普通股，注(下文簡稱爲「A類普通股」)。蘋果公司CEO庫克大規模拋售股票，套現逾3億港元，資金已存入上市公司設立的專項帳戶(「信託帳戶」)，以公共股東(定義詳見下文)爲受益人的註冊聲明(FORM S-1)中所規定的一定金額及特定款項。信託帳戶中持有的基金類型(包括資金持有的利息)除支付公司稅費以外，一旦實現以下最早的情況之一即可支取: (i) 完成首次（業務）組合；(ii) 如果公司未能在2025年3月3日之前完成首次（業務）組合，則可以贖回100%的發行股份（如下所述）；或 (iii) 股東表決贖回發行股份。 若要批准修訂本Amended and Restated Certificate，必須就修訂對決定最早如下情形之一的公司的義務以在首次業務組合中允許贖回或未在終止日期之前完成首次業務組合即贖回100%的發行股份產生影響或涉及股東權益或首次業務組合前的活動（如第9.7節所述），對修訂進行表決。發售期(「發售期」)所出售單位的組成部分的Common Stock股份的持有人(「發售股份」)，不論這些發售股份是在發售期內還是在發售市場上的二級市場中購買，也不論這些持有人是公司的發起人，高管或董事，或上述任何關聯方的子公司，均在此被稱爲「公共股東」。證券法第1933號修正案（以下稱「證券法」）證券法”), 與《證券法》下的註冊有關，並根據《證券法》第415條規定，隨時發行和銷售，可以一起或分開，可以分爲一個或多個系列（如適用）：
（i）公司的債務證券（“債務證券。”);
(ii) 公司普通股每股面值爲$0.001的股份（"普通股”);
(iii) 公司優先股每股面值爲$0.001的股份（"優先股”);
(iv) 用於購買債務證券、普通股或優先股的認股證（"權證”）;並
(v) 公司單位包括任何債務證券、普通股、優先股或認股權（"單位”).
債務證券、普通股、優先股、認股權證和單位在本文中統稱爲“證券。”債務證券將根據註冊聲明附表所附的實質相同的契約發行（“基礎信託協議”).
在下文表達的意見時，我們已經審查了原件或已由我們確認爲真實和完整副本的副本，形式爲基礎信託和其他文件、公司記錄、公司及公共官員的官員認證書、以及我們認爲有必要或建議的其他工具，以便我們能夠發表這些意見。在我們的審查中，我們假設所有簽名的真實性，所有自然人的法定資格和能力，提交給我們的所有文件的真實性，以及提交給我們的所有文件作爲副本的與原始文件一致性。關於這些意見所涉及的任何重要事實，我們已經根據我們認爲適當的程度依賴於公司及其他代表人員提供的聲明和陳述，而無需進行獨立調查。
吉布森德恩律師事務所 200 Park Avenue | New York, NY 10166-0193 | T: 212.351.4000 | F: 212.351.4035 | gibsondunn.com
San Francisco，加利福尼亞州94111-3715，艾梅巴卡德羅中心2600套房| 電話：415.393.8200 | 傳真：415.393.8306 | gibsondunn.com
Dianthus Therapeutics, Inc.
2024年10月1日
第2頁
我們在沒有獨立調查的情況下假設：
(i) 在根據註冊聲明銷售任何證券的時候（「銷售時點」），註冊聲明和其任何補充和修訂文件（包括事後生效修正文件）將生效並符合所有適用法律；相關時點”，註冊聲明及其任何補充和修訂（包括事後生效的修正）將生效並符合所有適用法律；
(ii)在相關時間，將準備一份簡介說明書並提交給委員會，用於描述通過其募集的所有與證券相關的文件而且該簡介說明書將符合所有適用法律;
（iii）所有證券將按照註冊聲明和適用的招股說明書中所述的方式發行和出售；
（iv）在相關時間，公司必須採取的所有法人或其他行動，以便合法授權每一次擬發行的證券和任何相關文件（包括（i）爲行使、轉換或交換任何證券以換取普通股或優先股而儲備普通股或優先股的情況（“可轉換安防-半導體），以及（ii）在有實物證券的情況下執行、交付和履行所需的證券及任何相關文件，這些文件在以下1至5段所述）已經得以完成，並仍然有效；
（v）發行任何普通股或優先股時，包括行使、轉換或交換任何可轉換證券時，發行和流通的普通股或優先股總數將不超過公司當時根據其公司章程及其他相關文件授權發行的普通股或優先股總數；
（vi）就債務證券而言，在相關時間，相關受託人應當依照1939年修訂的《信託契約法》（“信託工業法(TIA)”）獲得資格，受託人的資格聲明應以表格 T-1 應已向委員會遞交併關聯基礎契約應已由公司以及其他各方予以正式執行和交付，並在投資者關係協會下得到合法資格；
（七）在相關時間，有關任何已發行或發行的債券的決定性購買、承銷或類似協議以及與之相關的任何其他必要協議將已經獲得公司的所有必要董事會或其他行動的授權並由公司和其他相關方予以正式執行和交付。
Dianthus Therapeutics, Inc.
2024年10月1日
第3頁
根據上述內容並依賴於該內容，以及在此規定的假設、例外、限制和限定條件下，我們認爲：
| 1. | 關於任何債務證券，當： |
| a. | 該債務證券的條款和條件已根據相關基礎信託文件的條款和條件通過補充信託契約或公司證書正式制定， |
| b. | 任何此類補充信託契約已由公司和相關受託人正式執行和交付（連同相關基礎信託文件，稱爲“契約 |
| c. | 在適用的信託文件的條款下，這些債務證券已經執行（對於有證券的債務證券），交付和經過驗證，並根據適用的確切購買，承銷或類似協議頒發並出售。 |
這些債務證券將是公司的合法，有效和具有約束力的義務，並且按照各自的條款對公司執行。
| 2. | 關於任何優先股的股份： |
| a. | 涉及這些優先股的特許證書已經得到妥善執行，並已向特拉華州州務卿辦公室進行了備案。 |
| b. | 這些股票已經發行，（i）根據適用的確切購買，承銷或類似協議，並按照其中規定的有關代價頒發，或（ii）在行使，轉換或交換任何可轉換證券時，並且按照規定在此類可轉換證券或管理此類可轉換證券的工具中提供此類轉換或行使的額外代價，該代價（包括支付的任何用於此類可轉換證券的代價）不會少於優先股的面值。 每股 基礎上，在任何情況下，此類基礎不低於優先股的面值。 |
| c. | 任何此類可轉換證券均已有效發行並已完全支付 可免評估 （對於股票證券）或者公司的合法、有效和具有約束力的義務，根據其條款對公司可執行 |
此類優先股股份將會有效發行，並已完全支付 無需追加認繳款。
Dianthus Therapeutics, Inc.
October 1, 2024
Page 4
| 3. | With respect to shares of Common Stock, when: |
| a. | such shares of Common Stock have been duly executed (in the case of certificated shares) and delivered either (i) in accordance with the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, or (ii) upon conversion or exercise of any Convertible Security, in accordance with the terms of such Convertible Security or the instrument governing such Convertible Security providing for such conversion or exercise, and for any additional consideration specified therein, which consideration (including any consideration paid for such Convertible Security), on a per-share basis, shall in either event not be less than the par value of the Common Stock, and |
| b. | any such Convertible Security was previously validly issued and is fully paid and non-assessable (in the case of an equity Security) or is a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, |
such shares of Common Stock will be validly issued, fully paid and non-assessable.
| 4. | With respect to any Warrants, when: |
| a. | the warrant agreement relating to such Warrants (the “Warrant Agreement”), if any, has been duly executed and delivered by the Company and each other party thereto, |
| b. | the terms of the Warrants have been established in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and |
| c. | the Warrants have been duly executed (in the case of certificated Warrants) and delivered in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, |
such Warrants will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
| 5. | With respect to any Units, when: |
| a. | the unit agreement relating to the Units (the “Unit Agreement”), if any, has been duly executed and delivered by the Company and each other party thereto, |
| b. | the terms of the Units have been duly established in accordance with the Unit Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and |
| c. | the Units have been duly executed (in the case of certificated Units) and delivered in accordance with the Unit Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, |
the Units will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
Dianthus Therapeutics, Inc.
October 1, 2024
Page 5
The opinions expressed above are subject to the following exceptions, qualifications, limitations and assumptions:
A. We render no opinion herein as to matters involving the laws of any jurisdiction other than the State of New York and the United States of America and, for purposes of paragraphs 2 and 3 above, the Delaware General Corporation Law. We are not admitted to practice in the State of Delaware; however, we are generally familiar with the Delaware General Corporation Law as currently in effect and have made such inquiries as we consider necessary to render the opinions contained in paragraphs 2 and 3 above. This opinion is limited to the effect of the current state of the laws of the State of New York and the United States of America and, to the limited extent set forth above, the laws of the State of Delaware and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such laws or the interpretations thereof or such facts.
B. The opinions above with respect to the Indenture, the Debt Securities, the Warrants, the Warrant Agreement, the Units and the Unit Agreement (collectively, the “Documents”) are each subject to (i) the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors’ generally, including without limitation the effect of statutory or other laws regarding fraudulent transfers or preferential transfers, and (ii) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding in equity or at law.
C. We express no opinion regarding the effectiveness of (i) any waiver of stay, extension or usury laws; (ii) provisions relating to indemnification, exculpation or contribution, to the extent such provisions may be held unenforceable as contrary to public policy or federal or state securities laws or due to the negligence or willful misconduct of the indemnified party; (iii) any provision in any Document waiving the right to object to venue in any court; (iv) any agreement to submit to the jurisdiction of any Federal court; (v) any waiver of the right to jury trial; or (vi) any provision to the effect that every right or remedy is cumulative and may be exercised in addition to any other right or remedy or that the election of some particular remedy does not preclude recourse to one or more others.
Dianthus Therapeutics, Inc.
October 1, 2024
Page 6
D. To the extent relevant to our opinions in paragraphs 4 and 5 and not covered by our opinions in paragraphs 1, 2 or 3, we have assumed that any securities underlying, comprising or issuable upon exchange, conversion or exercise of any Warrants or Units are validly issued, fully paid and non-assessable (in the case of an equity security) or a legal, valid and binding obligation of the issuer thereof, enforceable against such issuer in accordance with its terms.
You have informed us that you intend to issue Securities from time to time on a delayed or continuous basis, and we understand that prior to issuing any Securities pursuant to the Registration Statement (i) you will advise us in writing of the terms thereof, and (ii) you will afford us an opportunity to (x) review the operative documents pursuant to which such Securities are to be issued or sold (including the applicable offering documents), and (y) file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary or appropriate.
We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption “Legal Matters” in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
| Very truly yours, |
| /s/ Gibson, Dunn & Crutcher LLP |